Ruby Bio is a technology company.
Ruby Bio has raised $8.0M across 1 funding round.
Ruby Bio has raised $8.0M in total across 1 funding round.
Ruby Bio has raised $8.0M in total across 1 funding round.
Ruby Bio's investors include Bascom Ventures, IBX, Kenneth Griffin.
Ruby Bio is an early-stage biotechnology company founded in 2022 that develops a proprietary biosynthesis platform using naturally occurring yeast to convert low-cost sugar feedstocks into high-value, biodegradable, and non-toxic compounds.[1][2][4] It primarily serves manufacturers in personal care (e.g., cosmetics, skincare, hair care), home care (e.g., cleaning agents), food and beverage, industrial, and agricultural sectors by providing sustainable alternatives to traditional chemical synthesis, enabling eco-friendly production at scale in their San Carlos, California facility.[1][2][5] The company has raised $5.14M and operates from Oakland, California, with strong early momentum from expert founders and investor backing like Alumni Ventures.[2][3]
Ruby Bio was founded in 2022 by CEO/co-founder Charlie Silver, a serial entrepreneur with experience scaling Mission Bio (raising over $120M), and leading product/technology at Novelx (NYSE:A), Agilent, and national labs like Lawrence Berkeley and NASA.[4] Key team members include Pavan, who scaled biosynthesis at startups like Greenlight (NASDAQ:GRNA), Clara Foods, and Eat Just (securing first regulatory approval for cultured chicken), and Harshal, a food science leader from Tyson Foods, Clara Foods, PepsiCo, and Roquette.[4] The idea emerged from their combined expertise in fermentation, precision biotech, and sustainable chemicals, addressing the need for scalable, green production of complex molecules amid rising demand for eco-friendly ingredients; early traction includes facility setup in San Carlos and funding within two years.[1][2][4][5]
Ruby Bio stands out in biotech through these key strengths:
Ruby Bio rides the sustainable biotech wave, capitalizing on global shifts toward circular economies and regulations favoring bio-based materials over fossil fuels, especially in consumer goods facing scrutiny for environmental impact.[1][2][3] Timing aligns with post-2020 investor surge in precision fermentation (peers like Eat Just, Clara Foods), amplified by supply chain disruptions and demand for local, scalable green chemistry in California hubs.[2][4] Market forces like rising costs of synthetic chemicals and consumer preference for "clean" labels propel adoption, while Ruby influences the ecosystem by lowering barriers to bio-ingredients, fostering innovation in personal care and food sectors akin to how early fermenters disrupted proteins.[1][3][5]
Ruby Bio is poised for expansion by hiring roles like Director of Chemistry to scale surfactant pipelines and pilot production, targeting commercial deals in high-growth areas like bio-based home care and food.[5] Trends in regulatory tailwinds for sustainable ingredients and AI-optimized bioprocesses will accelerate their trajectory, potentially mirroring Mission Bio's growth path with follow-on funding. Their influence could evolve from niche supplier to platform leader, reshaping chemical manufacturing toward yeast-driven sustainability and amplifying biotech's role in decarbonizing consumer industries—echoing their founding mission to make high-value chemicals eco-friendly at scale.[2][4][5]
Ruby Bio has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $8.0M Seed | Bascom Ventures, IBX, Kenneth Griffin |